Modified-live PRRS vaccine with innovative chimeric construction.
Pharmgate Animal Health announces PRRSGard®, an innovative, modified-live vaccine, has received USDA approval extending expiratory dating from 18 to 24 months.
“Eighteen months is the USDA standard for live vaccines, but our extended stability data confirm the product is stable, resulting in the approval of the 24-month expiration dating in November,” says Betsy Conarchy, biological regulatory affairs & quality manager for Pharmgate. “Producers and veterinarians now can have even more confidence in using the vaccine.”
PRRSGard® is a 1.0 milliliter, single-dose recombinant chimeric vaccine for Porcine Reproductive and Respiratory Syndrome (PRRSV). It features:
- An attenuated, lineage 1 PRRSV strain as a vaccine backbone
- A virulent, contemporary lineage 1 PRRSV field isolate, MN 184
- A non-encoding RNA sequence is inserted into the genome. This unique genetic marker allows diagnostic assay differentiation from “wild-type” virus strains.
Trials show that PRRSGard® promotes broad cross-strain immunity, reduced lung lesions and viremia, a low vaccine virus shed and spread following a challenge. It has been shown to reduce performance loss from pneumonia associated with PRRSV in growing pigs.
Take the next step with a vaccine uniquely designed for effective PRRSV protection. Learn more about the new PRRSGard® vaccine at prrsgard.com.
Founded in 2008, Pharmgate Animal Health is headquartered in Wilmington, North Carolina, and provides innovative and high-quality products that help the livestock industry optimize animal health, efficiency and production.
The company’s pharmaceutical production facilities are in Omaha, Nebraska with vaccine research and manufacturing operations based in St. Paul, Minnesota. To learn more about Pharmgate Animal Health, visit pharmgate.com